VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 2, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(SRBCF)(ZSB.F) is pleased to announce the signing of a Letter of Intent (LOI) for a collaboration with Biogalenys. The goal of the collaboration is to study Sirona Biochem's patented glycoprotein (cell preservation) technology and to develop preclinical data supporting multiple targeted applications.
Using its proprietary chemistry technique, Sirona Biochem has developed and patented a cell preservation technology that (early tests have shown) protects human fibroblast cells from damage in stressed environments. Potential applications of this technology include, but are not limited to: anti-aging cream, sunscreen / UV protection, wound care, reduced scarring, frostbite protection, stem cell preservation, beta islet cell preservation, platelet and red blood cell preservation, and increased preservation times for tissue explants and organ transplantation.
The proposed 3 year collaboration will focus on first studying the application of Sirona Biochem's cell preservation technology for use as a cosmetic anti-aging active ingredient and as a preservative adjuvant for tissue explants.
"We are excited to be creating a second project partnership with Biogalenys," said Neil Belenkie, CEO of Sirona Biochem. "We look forward to continuing the success that our companies achieved on our skin lightening project; applying our shared expertise in the study and development of our new cell preservation technology".
"We are extremely happy to continue our collaboration with Sirona Biochem and to work in partnership on their scientific innovations in the future, which will allow the simultaneous development of our two companies on an international level," said Pascal Svinareff, CEO of Biogalenys.
Biogalenys is a French laboratory (CRO) specialized in studies of transmembrane passage across several models of epithelia. Biogalenys provides, tests according to GLP or not, for active ingredients and chemical compounds and biological assays to serve the pharmaceutical and cosmetic industries. The laboratory designs the studies, conduct assays, completes data interpretation and classifies the absorption potential of drug and compounds, using different models for in-vitro, in-vivo and ex-vivo assays. Biogalenys is involved in several projects (approved by Cosmetic Valley) in research in cosmetic using efficient test with culture cells models.
For more information please visit: http://www.biogalenys.com
About Sirona Biochem
Sirona Biochem is a biotechnology company that specializes in fluorinating carbohydrate compounds, patenting the resulting new chemical entities, and licensing each compound for additional study and commercialization. Sirona Biochem's pipeline for development includes diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic and pharmaceutical use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit: www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.